Information:
Fel:
ID
12292
Beskrivning
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072
Nyckelord
Versioner (3)
- 2015-09-30 2015-09-30 -
- 2015-10-27 2015-10-27 -
- 2015-11-03 2015-11-03 - Julian Varghese
Uppladdad den
3 november 2015
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
CLL History BO17072 NCT00090051
History of Chronic lymphocytic leukemia NCT0090051
- StudyEvent: ODM
Similar models
History of Chronic lymphocytic leukemia NCT0090051
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Date
Item
Date of first diagnosis
date
C2316983 (UMLS CUI [1])
CL Item
yes (-> specify below) (1)
C1705108 (UMLS CUI-1)
CL Item
no (2)
C1298908 (UMLS CUI-1)
CL Item
A (1)
C2698392 (UMLS CUI-1)
CL Item
B (2)
C2698393 (UMLS CUI-1)
CL Item
C (3)
C2698394 (UMLS CUI-1)
Date of last progression
Item
Date of last progression
date
C0011008 (UMLS CUI [1])
CL Item
peripheral blood (1)
C0229664 (UMLS CUI-1)
CL Item
lymph nodes (2)
C0024204 (UMLS CUI-1)
CL Item
bone marrow (3)
C0005953 (UMLS CUI-1)
CL Item
other (-> specify below) (4)
C0205394 (UMLS CUI-1)
Other progression
Item
Other progression
text
C0178874 (UMLS CUI [1])
CL Item
A (1)
C2698392 (UMLS CUI-1)
CL Item
B (2)
C2698393 (UMLS CUI-1)
CL Item
C (3)
C2698394 (UMLS CUI-1)
CL Item
1 (1)
CL Item
2 (2)
CL Item
3 (3)
Item
Amendment C onwards
integer
C1704632 (UMLS CUI [1])
CL Item
1 (1)
CL Item
2 (2)
CL Item
3 (3)